Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed [Yahoo! Finance]
Nasus Pharma Ltd. Ordinary Shares (NSRX)
Company Research
Source: Yahoo! Finance
Previous clinical study demonstrated NS002 can achieve faster and higher absorption of epinephrine compared to an autoinjector Dosing of the first participant in the Phase 2 study in Canada reflects the successful initiation of the Company's needle-free epinephrine delivery program for anaphylaxis treatment Interim results are expected in the first quarter of 2026 TEL AVIV, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the successful initiation of the Company's Phase 2 clinical study with dosing of the first participant in Canada. The trial aims to evaluate NS002, the Company's investigational intranasal epinephrine powder formulation, compared to EpiPen for the treatment of anaphylaxis. NS002 could potentially offer patients a needle-free alternative to traditional epine
Show less
Read more
Impact Snapshot
Event Time:
NSRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NSRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NSRX alerts
High impacting Nasus Pharma Ltd. Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NSRX
News
- Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial OfficerGlobeNewswire
- Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant DosedGlobeNewswire
- Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine PowderGlobeNewswire
- Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program [Yahoo! Finance]Yahoo! Finance
- Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine ProgramGlobeNewswire
NSRX
Sec Filings
- 11/20/25 - Form 6-K
- 11/18/25 - Form 6-K
- 11/13/25 - Form SCHEDULE
- NSRX's page on the SEC website